Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor
References
Abramowski D, Staufenbiel M (1995) Identification of the 5-hydroxytryptamine2C receptor as a 60-kDaN-glycosylated protein in choroid plexus and hippocampus. J Neurochem 65:782–790
Appel NM, Mitchell WM, Garlick RK, Glennon RA, Teitler M, De Souza EB (1990) Autoradiographic characterization of (±)-1-(2,5-dimethoxy-4-[125I]iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1C receptors in the rat brain. J Pharmacol Exp Ther 255:843–857
Beasley CM, Masica DN, Potvin JH (1992) Fluoxetine: a review of receptor and functional effects and their clinical implications. Psychopharmacology 107:1–10
Benfield P, Heel RC, Lewis SP (1986) Fluoxetine — a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32:481–508
Caccia S, Fracasso C, Garattini S, Guiso G, Darati S (1992) Effects of short- and long-term administration of fluoxetine on the monoamine content in rat brain. Neuropharmacology 31:343–347
Canton H, Verrièle L, Colpaert FC (1990) Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2C sites: clozapine potently interacts with 5-HT1C sites. Eur J Pharmacol 191:93–96
Cheetham SC, Viggers JA, Slater NA, Heal DJ, Buckett WR (1993) [3H]Paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments. Neuropharmacology 32[8]:737–743
Conn PJ, Sanders-Bush E (1986) Agonist-induced phosphoinositide hydrolysis in choroid plexus. J Neurochem 47:1754–1760
Fabre LF, Crismon ML (1985) Efficacy of fluoxetine in outpatients with major depression. Curr Ther Res 37[1]:115–123
Fuller RW, Snoddy HD, Perry KW, Bymaster FP, Wong DT (1978) Importance of duration of drug action in the antagonism ofp-chloroamphetamine depletion of brain serotonin — comparison of fluoxetine and chlorimipramine. Biochem Pharmacol 27:193–198
Gerione RA, Codina J, Benovic JL, Lefkowitz RJ, Birnbaumer L, Caron MG (1984) The mammalian beta 2-adrenergic receptor: reconstitution of functional interactions between pure receptor and pure stimulatory nucleotide binding protein of the adenylate cyclase system. Biochemistry 23:4519–4525
Han C, Minneman KP (1991) Interaction of subtype-selective antagonists with α1-adrenergic receptor binding sites in rat tissues. Mol Pharmacol 40:531–538
Harker EL, Westphal RS, Schmidt D, Sanders-Bush E (1994) Constitutively active 5-hydroxytryptamine 2C (5-HT2C) receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 269:11687–11690
Havlik S, Peroutka SJ (1992) Differential radioligand binding properties of [3H]5-hydroxytryptamine and [3H]mesulergine in a clonal 5-hydroxytryptamine2C cell line. Brain Res 584:191–196
Hietala J, Salonen I, Lappalainen J, Syvälahti E (1990) Ethanol administration does not alter dopamine D1 and D2 receptor characteristics in rat brain. Neurosci Lett 108:289
Hietala J, Koulu M, Kuoppamäki M, Lappalainen J, Syvälahti E (1992) Chronic clozapine treatment down-regulates serotonin 5-HT-1c receptors in rat brain. Prog Neuropsychopharmacol Biol Psychiatry 16:727–732
Hoffman BJ, Mezey E (1989) Distribution of serotonin 5-HT1C receptor mRNA in adult rat brain. FEBS Lett 247[2]:453–462
Jenck F, Moreau J-L, Mutel V, Martin JR, Haefely WE (1993) Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 231:223–229
Karson CN, Newton JEO, Livingston R, Jolly JB, Cooper TB, Sprigg J, Komoroski RA (1993) Human brain fluoxetine concentrations. J Neuropsychiatr Clin Neurosci 5:322–329
Kuoppamäki M, Syvälahti E, Hietala J (1993) Clozapine andN-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur J Pharmacol [Mol Pharmacol Sect] 245:179–182
Kuoppamäki M, Pälvimäki E-P, Syvälahti E, Hietala J (1994) 5-HT1C receptor-mediated phosphoinositide hydrolysis in the rat choroid plexus after chronic treatment with clozapine. Eur J Pharmacol 255:91–97
Kuoppamäki M, Pälvimäki E-P, Hietala J, Syvälahti E (1995) Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropsychopharmacology 13:139–151
Laakso A, Pälvimäki E-P, Kuoppamäki M, Suvälahti E, Hietala J (1996) Chronic citalopram and fluoxetine treatments up-regulate 5-HT2C receptors in the rat choroid plexus. Neuropsychopharmacology (in press)
Leonhardt S, Gorospe E, Hoffman BJ, Teitler M (1992) Molecular pharmacological differences in the interaction of serotonin with 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. Mol Pharmacol 42:328–335
Leysen JE, Niemegeers CJE, Van Nueten JM, Laduron PM (1982) [3H]Ketanserin (R 41 468), a selective3H-ligand for serotonin2 receptor binding sites; binding properties, brain distribution and functional role. Mol Pharmacol 21:301
Mann CD, Bich Vu T, Hrdina PD (1995) Protein kinase C in rat brain cortex and hippocampus: effect of repeated administration of fluoxetine and desipramine. Brit J Pharmacol 115:595–600
Milligan G, Bond RA, Lee M (1995) Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trneds Pharmacol Sci 16:10–13
Molineaux SM, Jessell TM, Axel R, Julius D (1989) 5-HT1C receptor is a prominent serotonin receptor subtype in the central nervous system. Proc Natl Acad Sci USA 86[17]:6793–6797
Morin D, Zini R, Urien S, Tillement JP (1989) Pharmacological profile of binedaline, a new antidepressant drug. J Pharmacol Exp Ther 249[1]:288–296
Pazos A, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 346:205–230
Pompeiano M, Palacios JM, Mengod G (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res Mol Brain Res 23[1–2]:163–178
Richelson E, Pfenning M (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104:277–286
Rickels K, Amsterdam JD, Avallone MF (1986) Fluoxetine in major depression: a controlled study. Curr Ther Res 39[4]:559–563
Roth BL, Hamblin MW, Ciaranello RD (1991) Mianserin decreases 5-HT2 radioligand binding without altering 5-HT2 receptor mRNA levels. Eur J Pharmacol 207:169–172
Roth BL, Ciaranello RD, Meltzer HY (1992) Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 260:1361–1366
Sanders-Bush E, Breeding M (1988) Putative selective 5-HT-2 antagonists block 5-HT-1c receptors in the choroid plexus. J Pharmacol Exp Ther 247:169–173
Sanders-Bush E, Breeding M (1990) Serotonin1c receptor reserve in choroid plexus masks receptor subsensitivity. J Pharmacol Exp Ther 252[3]:984–988
Sommi RW, Crismon ML, Bowden CL (1987) Fluoxetine: a serotonin-specific, second-generation antidepressant. Pharmacotherapy 7[1]:001–015
Torok-Both GA, Baker GB, Coutts RT, McKenna KF, Aspeslet LJ (1992) Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron-capture detection. J Chromatogr 579:99–106
Westphal RS, Sanders-Bush E (1994) Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists. Mol Pharmacol 46:937–942
Wong DT, Threlkeld PG, Robertson DW (1991) Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology 5[1]:43–47
Wood MD, Glen A, Blackburn TP, Lee JA, Sutiphong JA, Kumar C, Carey J, Robinson J (1993) (-)-Fluoxetine has high affinity for the cloned rat and human 5-HT1C receptor and the human 5-HT2 receptor. Br J Pharmacol 110 [Proceedings Supplement]: 102P